 |
인쇄하기
취소
|
Anterogen’s stem cell-based anal fistula drug gets green light from KFDA
The Korea Food and Drug Administration said Thursday that it has approved Cupistem, a stem cell-based anal fistula drug by Anterogen Co., a subsidy of Bukwang Pharmaceutical Co.
Anterogen’s Cupistem is a stem cell treatment that uses a patient’s own stem cells from fatty tissue to treat anal fistula in Crohn’s disease.
In a clinical trial where 33 patients were enrolled with Cupistem, the...
Anterogen’s Cupistem is a stem cell treatment that uses a patient’s own stem cells from fatty tissue to treat anal fistula in Crohn’s disease.
In a clinical trial where 33 patients were enrolled with Cupistem, the...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.